Author Correction: Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma

Author Correction: Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma

Bibliographic Details
Main Authors:	Hankang Wang, Congcong Gao, Xiaodong Li, Feng Chen, Guijie Li
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-04-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-59647-7

Similar Items

Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma
by: Hankang Wang, et al.
Published: (2024-03-01)

Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma
by: Qian Liu, et al.
Published: (2021-06-01)

Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model
by: Fanguang Meng, et al.
Published: (2022-10-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Iron accumulation and lipid peroxidation: implication of ferroptosis in hepatocellular carcinoma
by: Xiaodong Li, et al.
Published: (2024-01-01)

Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study
by: Wei-Li Xia, et al.
Published: (2022-09-01)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
by: Yang X, et al.
Published: (2020-05-01)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
by: Dengdeng Pan, et al.
Published: (2022-05-01)

Correction: Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin.
by: Artur Veloso, et al.
Published: (2013-01-01)

Correction: Genome-Wide Transcriptional Effects of the Anti-Cancer Agent Camptothecin
Published: (2013-01-01)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum]
by: Yang X, et al.
Published: (2020-06-01)

Aortic Dissection in Apatinib Treatment of Advanced Hepatocellular Carcinoma: A Case Report
by: LI Fubo, et al.
Published: (2019-07-01)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
by: Gehan Xu, et al.
Published: (2022-10-01)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
by: Wu-tong Ju, et al.
Published: (2022-09-01)

Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
by: Qicong Luo, et al.
Published: (2023-05-01)

The Anti-HIV Actions of 7- and 10-Substituted Camptothecins
by: Yu-Ye Li, et al.
Published: (2009-12-01)

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
by: Anan Gong, et al.
Published: (2022-03-01)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
by: Hongzhi Wang, et al.
Published: (2022-07-01)

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
by: Tian-Qi Zhang, et al.
Published: (2023-10-01)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
by: Xiaoying Gu, et al.
Published: (2022-10-01)

Synthesis of (+)-camptothecin
by: Subhash P. Chavan, et al.
Published: (2005-01-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
by: Julu Huang, et al.
Published: (2023-08-01)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
by: Yuhua Wei, et al.
Published: (2022-01-01)

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Qing Yang, et al.
Published: (2023-03-01)

Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
by: Tao Sun, et al.
Published: (2020-12-01)

Genome-wide transcriptional effects of the anti-cancer agent camptothecin.
by: Artur Veloso, et al.
Published: (2013-01-01)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)

The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
by: Wang H, et al.
Published: (2021-09-01)

Galactosed and Reduction-Responsive Nanoparticles Assembled from Trimethylchitosan–Camptothecin Conjugates for Enhanced Hepatocellular Carcinoma Therapy
by: Chen Fu, et al.
Published: (2022-06-01)

Camptothecin-20(s)-O-[N-(3’α,12’α-dihydroxy-24’-carbonyl-5’β-cholan)]-lysine, a Novel Camptothecin Analogue, Induces Apoptosis towards Hepatocellular Carcinoma SMMC-7721 Cells
by: Chunfei Jiang, et al.
Published: (2011-09-01)

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma
by: Lixuan Cui, et al.
Published: (2021-11-01)

Efficacy and safety of anti-PD-1 monotherapy anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience
by: Qingyan Liu, et al.
Published: (2023-10-01)

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
by: Xiaofeng Chen, et al.
Published: (2024-03-01)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
by: Qingli Cui, et al.
Published: (2022-10-01)

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
by: Maohua Li, et al.
Published: (2022-03-01)

Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib
by: Fang Sun, et al.
Published: (2024-04-01)

Low Doses of Camptothecin Induced Hormetic and Neuroprotective Effects in PC12 Cells
by: Chao Zhang, et al.
Published: (2015-06-01)

Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Frontiers Editorial Office
Published: (2024-02-01)